Kornimate/medical-research-clean huggingface dataset:
pulmonary and extrapulmonary impacts of covid-19 on young adults

Conditions: Post COVID-19

Summary: when the literature search is conducted, it is seen that there are many studies examining the effects of covid-19 disease on individuals in various disease groups (ms, stroke, parkinson, copd, asthma, etc.) and age groups (adult, geriatric, etc.). however, it has been determined that there is no study examining the impacts of this disease on functional capacity, physical activity, pulmonary function, emotional state, sleep, and quality of life in healthy young adults. this study will reveal whether covid-19 disease causes an effect on the mentioned parameters in young adults. the aim of recent study is to investigate functional capacity, respiration, pain, depression, sleep and quality of life in young adults post covid-19. for this purpose, participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, o2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. in addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods. the goals of recent work, * to determine whether covid-19 disease causes a decrease in functional capacity and changes in respiratory parameters in young adults, as well as to determine whether there are effects such as pain, depression, decreased sleep and quality of life, * to determine whether there are significant changes in the values of the relevant outcome measurements in all the mentioned parameters, * as a result of these, to determine the effects of covid-19 disease on these parameters in young adults with objective, measurable data and to guide researchers and clinicians who do/will conduct studies on the subject.


Eligibility criteria:
inclusion criteria: * volunteers who are aged between 18-45 years * cases, who were infected with covid-19 and had at least 12 weeks after diagnosis * cases, who have no symptoms of covid-19 such as fever, cough, ageusia, anosmia, diarrhea, arthralgia, myalgia, sore throat, headache, chest pain exclusion criteria: * those have any cardiac or pulmonary disease history * those have diagnoses of any psychological disease (major depression, anxiety disorder, etc.) * those have any neurological or orthopaedic disease which hinders participation in physical activity

Keywords: covid-19 respiration physical capacity sleep muscle strength 6-minute walking test
energy labelling for alcohol drinks in new zealand: consumers perceptions and impacts on purchase behaviour

Conditions: Consumption, Alcohol; Drinking, Alcohol

Summary: a two-stage qualitative and quantitative study to provide insight into consumers' awareness of energy in alcoholic beverages, and how energy labelling effects consumer behaviour.

rationale: in 2016/2017, one in five (19.5%) new zealand adults (≥15 years and older) had an alcohol drinking pattern that carriers a risk of harming the drinker or another, and one in three (32.9%) young adults aged 18 to 24 years are hazardous drinkers. to reduce alcohol-related harm and help new zealanders make positive decisions about their alcohol use, strategies are needed that not only inform them about health risks but also alter the environment they find themselves in on a daily basis. unlike most packaged food products, alcoholic beverages are not required to present a statement of the composition of the product, such as amount of alcohol, energy or the nutrient content. it has been suggested that in the absence of this information, consumers of alcohol have no idea how much energy, alcohol or kilojoules they are consuming. research indicates that nutrition labelling of food and non-alcoholic beverage products does impact consumer perceptions and product evaluations. a recent poll by stuff showed that 83% of 3,300 new zealanders indicated that they want to know what they are consuming and supported placement of ingredients and nutritional information on alcohol products. objectives: to provide insight into consumers' awareness of energy in alcoholic beverages, and in their views on energy labelling of alcoholic beverages. the project also aims to explore the effects of different types of energy labelling on consumers alcohol purchase behaviour. design: two-staged qualitative and quantitative study. * qualitative stage: focus groups. * quantitative stage: four-arm randomised controlled trial. this qualitative stage aims to test the effects of three different types of alcohol energy labels on alcoholic beverages on (online) purchase behaviour, compared to a control (no label) condition, using an 'online shopping cart'. recruitment: panel. sample size: qualitative stage: n=36 (six focus groups with six people per group); quantitative stage: n=600 (n=150 participants per experimental condition).

Eligibility criteria:
inclusion criteria: * are ≥18 years of age; * having purchased and consumed at least one alcoholic beverage in the past month; * be able to read english; * reside in new zealand; * be a member of the online panel of "research now survey sampling international". exclusion criteria: * participants not meeting the eligibility criteria will be excluded.

Keywords: consumer behaviour alcohol labelling energy labelling
dietary intervention to improve cardiometabolic risk profile in individuals with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases

Summary: this is a randomized controlled trial to examine whether personalized guidance to increase the consumption of fiber rich food items according to the dutch dietary guidelines, compared to usual care, improves health of individuals with type 2 diabetes.

previous interventions with fibre supplements show promising results among individuals with type 2 diabetes, but wether these effects are similar when higher fiber intake is achieved through diet and not through supplements remains unclear. the primary objective of this study is to investigate the effects of personalized dietary guidance to increase the intake of fibre-rich foods, as recommended in the dutch dietary guidelines, on cardiometabolic risk profile in individuals who have type 2 diabetes, compared to usual care after six months. the study is a parallel randomized trial over a period of twelve months, including an intervention period of six months and a follow up period of six months. the study population consists of adults with non-insulin-dependent type 2 diabetes, diagnosed by a medical doctor at least 6 months prior to study enrolment.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes made by a medical doctor at least 6 months prior to study enrolment * adult * willing and able to follow dietary intervention * willing to participate in both intervention and control group * living at a reasonable distance from the research center at wageningen university \& research (wur) (i.e.maximum of ± 1 hour away) exclusion criteria: * currently treated with insulin therapy * recently (\< 6 months) or currently being under supervision of a dietician * pregnant or breast-feeding * history of bariatric surgery, including gastric banding * current participation in a study with an investigational drug or dietary intervention * excessive alcohol consumption (more than 14 units for males/7 units for females per week) or drug use * clinical disorders that could interfere with the intervention (e.g. gastro-intestinal disorders, auto-immune diseases, psychiatric disorders, uncontrolled heart diseases, serious neurological disorders, renal failure or cancer) * not able to speak and understand the dutch language * no general practitioner * working at the department of human nutrition and health at wageningen university \& research

Keywords: dietary guidelines dietitian dietary fiber diabetes type 2 nutrition randomized controlled trial (rct) cardiovascular diseases
evaluate the efficacy and safety of intense pulsed light filters combined with oral medication in the treatment of acne

Conditions: Acne Vulgaris

Summary: 1. acne is a chronic inflammatory disease involving the hair follicles and sebaceous glands, characterized by acne, papules, pustules, nodules, and cysts. acne often occurs in sebum overflow areas such as the face, chest, back and so on. it is a common skin lesion, which not only affects physical health, but also brings psychological disorders and psychosocial problems to patients. at present, the common treatment methods of acne include health education, topical drugs, oral drugs and medical cosmetic treatment. 2. intense pulsed light has been widely accepted as a non-invasive and non-serious treatment for acne. the m22 strong light and laser system acne filter has a wavelength of 400-600/800-1200nm. 3. although there are many treatments for acne, the slow response and easy recurrence of acne are still common problems that trouble doctors and patients. we clinically use drugs combined with intense pulsed light treatment, and the efficacy of the patients is fair, but currently lack of clinical research data support. this study intends to evaluate the effectiveness of different methods in the treatment of moderate and severe acne by evaluating different bands of intense pulsed light combined with drugs, and to observe whether the treatment with oral tetracycline antibiotics combined with intense pulsed light is safe.

the m22 strong light and laser system acne filter has a wavelength of 400-600/800-1200nm. the light in the 400-600nm band is targeted at the superficial skin inflammation, while 800-1200nm is targeted at the deep sebaceous gland inflammation. the skin can produce oxidation reaction to form singlet oxygen to eliminate propionibacterium acnes after absorption of porphyrin at 400nm. the light of 800-1200nm band can penetrate into the deep layer of sebaceous glands, and the thermal contraction of sebaceous glands can improve the anaerobic environment of bacteria, which is not conducive to the reproduction of bacteria. meanwhile, when the temperature of sebaceous glands reaches 40 degrees celsius, bacteria can be killed directly.

Eligibility criteria:
inclusion criteria: * age 18-40, regardless of gender; the patient agrees to participate in this trial and signs the informed consent clinical diagnosis of acne (moderate and severe) no bleeding, rupture, infection or other conditions affecting the visual field of laser surgery. exclusion criteria: * persons with facial dermatitis and sensitive skin; relevant treatment within 1 month, including topical drugs, oral drugs, medical cosmetic treatment; those with a history of exposure to the sun in recent january; persons with scar constitution; skin malignant tumor or precancerous lesion; diabetes, heart disease, epilepsy, connective tissue disease, etc.; pregnant or breastfeeding; recent skin infections (such as viruses; bacteria); those who are using other methods to treat similar diseases; others are not suitable for enrollment.

Keywords: acne vulgaris intense pulsed light oral medication
nutritional and physical exercise intervention in older patients with malignant hemopathies

Conditions: Hematologic Malignancy; Old Age; Debility

Summary: clinical trial to analyze the impact of nutrition and physical exercise intervention program on the completion of treatment in older patients 70 years or older with malignant hemopathology

objective: this study aims to determine wether a geriatric intervention based on an individualized program of physical exercise and nutritional support improves the ability to complete oncological treatment at the doses and time initially planned in patients ≥ 70 years affected by hematological malignancies. design: prospective, clinical trial, randomized, parallel and open groups. setting: patients ≥ 70 years recently diagnosed of malignant hematological pathology in a comprehensive cancer center intervention: all those patients who meet the inclusion criteria and agree to participate, will sign the corresponding informed consent and will be assessed through a cga (comprehensive geriatric assessment), that includes the performance of a physical condition test (sppb), and randomized to the study group or control group. patients in the study group will participate in an intervention program with nutritional support and physical exercise during the period in which they are receiving oncological treatment or for a maximum period of 6 months. the patients of the control group will pass to follow up. all patients, regardless of the branch of study to which they are assigned, will receive the oncological treatment indicated by their doctor and a standard follow-up according to the current care protocols in the center. determinations: main variable: proportion of adherence to treatment calculated as the percentage between the dose administered and the prescribed. adherence over 80% will be considered acceptable. secondary variables: geriatric, nutritional and physical-condition parameters before and after the intervention, quality of life before and after the intervention, toxicity and complications during treatment and response to treatment.

Eligibility criteria:
inclusion criteria: * hematological pathology (myelodysplastic syndromes, lymphoproliferative syndromes, multiple myeloma) * considered able to practice physical exercise * signed informed consent exclusion criteria: * other hematological pathology * considered unable to practice physical exercise

Keywords: older physical exercise nutrition support hematologic malignancies geriatric assessment geriatric intervention
to evaluate the safety and efficacy of pediococcus acidilactici pa53 in relieving constipation in adults

Conditions: Constipation

Summary: to study the improvement of constipation symptoms, quality of life and mental state, intestinal function, intestinal hormones, inflammation and immunity, and intestinal flora of constipation subjects after 8-week intervention with pediococcus acidilactici pa53.


Eligibility criteria:
inclusion criteria: 1. constipated subjects subjects (less than 3 bowel movements per week and/or bristol scale types 1 and 2); 2. be able to complete the research according to the requirements of the test plan; 3. subjects who have signed informed consent; 4. subjects (including male subjects) have no family planning and voluntarily take effective contraceptive measures from 14 days before screening to 6 months after the end of the trial. - exclusion criteria: 1. short-term use of items with similar functions to the subject, which affects the judge of the result; 2. those who changed their diet type during the study period; 3. people with severe allergies and immune deficiencies; 4. women who are pregnant, breastfeeding or planning to become pregnant; 5. patients with serious diseases of cardiovascular, lung, liver, kidney and other vital organs, diabetes, thyroid disease, severe metabolic diseases, malignant tumors, and severe immune system diseases; 6. people who have used antibiotics in the past two weeks; 7. people with serious mental and mental illness; 8. failure to eat the test sample as required, or failure to follow up on time, resulting in uncertain efficacy; 9. other researchers judged it inappropriate to participate. -
evaluate efficacy, safety & subject satisfaction of pain management with pliaglis® cream for dermal filler injections

Conditions: Nasolabial Folds

Summary: pliaglis® cream versus compounded topical anesthetic for pain management during restylane® injections for the correction of nasolabial folds.

open-label, randomized study designed to assess the effectiveness of a topical anesthetic (pliaglis® cream) versus a compounded topical anesthetic at needle stick, immediately after, one and three hours after restylane® injections in the nasolabial folds.

Eligibility criteria:
inclusion criteria: * male or female subjects 30 - 65 years of age * subject undergoing cosmetic dermal filler injections for correction of nasolabial folds. treatment sites should be comparable, requiring the same number of injections on each nasolabial fold * subjects diagnosed with moderate nasolabial folds (wrinkle severity rating scale of grade 3) exclusion criteria: * subjects under treatment for a dermatologic condition on the face, which may interfere with the safe evaluation of the study treatment (e.g. eczema, psoriasis, severe sun-damage, dermatitis), have damaged, denuded or broken skin at the designated treatment site and/or have scarring or infection of the area to be treated * subjects who have taken prescription or non-prescription analgesic medication during the 24 hour period prior to the procedure * subjects with a history of bleeding or clotting disorders * subjects who have used asa (aspirin), nsaids (non-steroidal anti- inflammatory drugs), anticoagulants, st. john's wort or high doses of vitamin e (above the recommended daily allowance) within 2 weeks prior to the procedure

Keywords: nasolabial folds wrinkles topical anesthetic
a clinical study of shr-1314 injection in the treatment of moderate to severe plaque psoriasis in adults

Conditions: Plaque Psoriasis

Summary: this is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase ii study to investigate the efficacy, safety, tolerability and pharmacokinetics of shr-1314 injection with moderate to severe plaque psoriasis in adults

this study was a multicenter, parallel, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy ,safety, tolerance, and pharmacokinetics (pk) of different shr-1314 dosing regimens in moderate to severe chronic plaque psoriasis in adults.

Eligibility criteria:
* inclusion criteria: * provide written informed consent before any study assessment is performed. * male or female at least 18 years of age at screening. * chronic plaque psoriasis history ≥ 6 months;at the time of randomization, moderate to severe plaque psoriasis. * subject is a candidate for systemic psoriasis therapy and/or phototherapy and/or chemo phototherapy. * the body mass index (bmi) was ≥18 kg/m2 and ≤35 kg/m2 at screening. * exclusion criteria: * diagnosis of psoriasis at screening is not chronic plaque psoriasis * severe infection or systemic infection before baseline * there are other skin problems that researchers believe will hinder the evaluation of psoriasis. * subject has a history or symptom of malignancy within 5 years prior to screening, regardless of whether or not treatment has been received, with or without signs of recurrence or metastasis. * the investigators believe that the subject is not suitable for any clinical condition involved in the clinical study. * those who are allergic to the study ingredients or excipients, or who are allergic to other biological agents. * there is evidence that hepatitis b, hepatitis c, or human immunodeficiency virus (hiv) confirmation test is positive. * subject's medical history, symptoms and examination results suggest active tuberculosis or latent tuberculosis. * laboratory tests have clinical implications at screening, and the investigators believe that participation in the study may pose unacceptable risks to the subject or impede data analysis. * women who are pregnant or breastfeeding at screening or at baseline * the investigator believes that it will prevent the subject from following and completing any other circumstances of the study protocol.
boat: beta blocker uptitration with optivol after cardiac resynchronization therapy (crt)

Conditions: Congestive Heart Failure

Summary: many heart failure patients are unable to reach target beta blocker doses. this study will address whether cardiac resynchronization therapy (crt) will enable uptitration of beta-blockers to target doses and whether it will favorably affect remodeling by reducing left ventricular end systolic volume (lvesv), with measurable clinical benefit, beyond crt alone (without changes in beta-blocker dose).

beta blockers have been proven to have benefit in heart failure (hf) patients with regard to morbidity and mortality. however, initiation and uptitration remains a challenge in many patients. worsening of heart failure, symptomatic hypotension and symptomatic bradycardia all limit up-titration to the target doses that have been shown to have mortality benefits (carvedilol \[coreg\] 25 mg bid, metoprolol succinate \[toprol-xl\] 200 mg qd) in the large clinical trials (copernicus, merit-hf). it is debated whether the benefit of beta-blockade is solely due to heart rate reduction or more broadly from the cardiac, central and peripheral effects of blocking sympathetic activity. clearly, there is a remodeling effect on the dilated ventricle. furthermore, patients with heart rates of 64 bpm or less are rarely begun on beta-blocker therapy. it is not known whether these patients should be given a pacemaker in order to then safely initiate beta-blocker therapy. it is also clear that isolated right ventricular pacing can have deleterious effects on ventricular dyssynchrony and symptomatic heart failure despite medical therapy. biventricular pacing (bivpm), also known as cardiac resynchronization therapy (crt), is the pacing mode of choice for patients with wide qrs complexes and symptomatic hf. it is hypothesized that crt therapy allows for increased beta -blocker dose (or initiation of beta-blocker in patients previously intolerant) with improved nyha, ejection fraction, and remodeling effects. the synergy between two established heart failure therapies requires further evaluation in a prospective randomized trial.

Eligibility criteria:
inclusion criteria: * nyha iii-iv * qrs \> 120 msec * on medical therapy, but beta blocker dose not @ target (carvedilol 25 bid, metoprolol succinate 200 qd) exclusion criteria: * qrs \< 120 msec * on target beta blocker dose

Keywords: heart failure beta blockers resynchronization congestive heart failure, nyha iii-iv candidate for bivpm not on target dose (coreg 25 bid or toprol xl 200 qd)
a study evaluating the associations between clinical characteristics and use of oral anticoagulants in italian elderly participants with non-valvular atrial fibrillation

Conditions: Non-Valvular Atrial Fibrillation (NVAF)

Summary: the purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (nvaf), in italy, and it's persistence rate after one year.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * diagnosis of any type (e.g. persistent, permanent, paroxysmal) of non-valvular atrial fibrillation (nvaf) documented in the participant's medical chart based on electrocardiogram (ecg) results, or diagnosed at enrollment * naïve to anticoagulant treatments, or not having received anticoagulant treatments during the 6 months prior to enrollment * multidimensional geriatric assessment (mga) performed at enrollment, or anyway no more than 3 months before in case of stable disease (i.e. no relevant events) in the previous 3 months exclusion criteria: * valvular atrial fibrillation (af) due to artificial heart valve * medical conditions (apart from nvaf) requiring anticoagulant therapy (such as deep vein thrombosis or pulmonary embolism) * use of inappropriate direct-acting oral anticoagulant (doac) doses based on the current summary of product characteristics (smpc) for any drugs

Keywords: atrial fibrillation oral anticoagulants